Using drug repositioning strategy, we discovered that triciribine phosphate monohydrate (TCN‐PM), the active metabolite of an AKT inhibitor triciribine with promising pharmacological efficacy in clinic trials, could specifically inhibit the growth of FLT3‐ITD mutant AML cancer cells as well as FLT3‐ITD primary AML cells (Figure 1A). This evidence concerns the gene FLT3 and cancer.